Keros Therapeutics Inc. (KROS)
NASDAQ · Healthcare
Keros Therapeutics Inc. Operating Income 2019–2025
Keros Therapeutics Inc. annual/quarterly operating income history and growth rate from 2019 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Keros Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -25.9 M, a 117.02% decrease year-over-year.
- Keros Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was 71.0 M, a 135.33% decrease year-over-year.
- Keros Therapeutics Inc. annual operating income for 2025 was 67.6 M, a 132.05% decrease from 2024.
- Keros Therapeutics Inc. annual operating income for 2024 was -210.8 M, a 24.06% increase from 2023.
- Keros Therapeutics Inc. annual operating income for 2023 was -169.9 M, a 48.05% increase from 2022.
- Keros Therapeutics Inc. annual operating income for 2022 was -114.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Keros Therapeutics Inc. Operating Income — FAQ
Keros Therapeutics Inc. (KROS) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is Keros Therapeutics Inc.'s operating income?
Keros Therapeutics Inc. (KROS) reported operating income of $68M for fiscal 2025.
Where can I see KROS's operating income history?
The chart and table above show Keros Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.